This week, the Commonwealth Fund released new findings from its Affordable Care Act Tracking Survey. The survey is a nationally representative telephone poll that tracks coverage rates among 19- to 64-year olds.
This week, the Commonwealth Fund released new findings from its Affordable Care Act Tracking Survey. The survey is a nationally representative telephone poll that tracks coverage rates among 19- to 64-year olds. The newest findings were from the February to March period of the survey, during which 2403 individuals were polled.
Respondents continue to worry about healthcare costs on all fronts, from general medical bills to the high cost of prescription drugs. When asked if they would have the money to pay $1000 medical bill within 30 days in the case of an unexpected medical emergency, nearly half (46%) of respondents said they would not have the money to cover such a bill in that timeframe.
Specifically, women, people of color, people who are uninsured, those with incomes under 250% of the poverty line ($30,150 for an individual), and those covered by Medicare or Medicaid were among the most likely to say they couldn’t pay the bill.
When participants were asked if whether over the past year their healthcare (including prescription drugs) had become harder to afford, easier to afford, or if there had been no change, the majority (66%) said there had been no change. However, people with individual market coverage were significantly more likely than those with employer coverage or Medicaid to say that healthcare had become harder to afford (24%). Of people polled, only 8% said healthcare had become easier to afford.
Finally, when asked if they were confident in their ability to afford healthcare if they were to become seriously ill, 62.4% of adults said they were very or somewhat confident that they could afford these costs, down from nearly 70% in 2015. There were also significant declines in confidence among young adults, women, those aged 50 to 64, and people with health problems.
In an effort to address growing concerns about the cost of drug prices in particular, President Donald Trump and HHS Secretary Alex Azar spoke jointly on Friday, April 11, providing an overview of a comprehensive blueprint HHS released to lower high drug prices in the United States.
“The blueprint is a sophisticated approach to reforming and improving this complex system…[but] this is not a one-and-done deal,” said Azar. “It is a comprehensive process, and as the president said, it will take time to reorder an entire complex multibillion-dollar system.”
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.